Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors

Yusuke Shiozawa, Kenneth Pienta, Russell S. Taichman

Research output: Contribution to journalArticle

Abstract

Despite significant improvements in therapy, the prognosis for cancer with bone metastasis is generally poor. Therefore, there is a great need for new therapeutic approaches for metastatic disease. It has been appreciated that tumor cells metastasize to bone using mechanisms similar to those of hematopoietic stem cells (HSC) homing to bone marrow (e.g., CXCL12/CXCR4). It was recently found that prostate cancer cells target the bone marrow microenvironment for HSCs, or the HSC niche, during metastasis. Of importance, these disseminated prostate cancer cells can be mobilized out of the niche with the use of HSC mobilizing agents. These findings suggest that the bone marrow HSC niche is a potential therapeutic target for metastatic disease. Therefore, a hypothesis worth considering is that agents that can disrupt the interactions between tumor cells and the HSC niche may be efficacious when used in conjunction with standard chemotherapeutic agents. Although further understanding of the tumor-niche interactions is needed, the concept of targeting the niche in conjunction with chemotherapy could open up new possibilities to eradicate incurable metastatic diseases.

Original languageEnglish (US)
Pages (from-to)5553-5558
Number of pages6
JournalClinical Cancer Research
Volume17
Issue number17
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Stem Cell Niche
Hematopoietic Stem Cells
Bone and Bones
Neoplasms
Prostatic Neoplasms
Bone Marrow
Neoplasm Metastasis
Therapeutics
Bone Neoplasms
Bone Marrow Cells
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. / Shiozawa, Yusuke; Pienta, Kenneth; Taichman, Russell S.

In: Clinical Cancer Research, Vol. 17, No. 17, 01.09.2011, p. 5553-5558.

Research output: Contribution to journalArticle

Shiozawa, Yusuke ; Pienta, Kenneth ; Taichman, Russell S. / Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 17. pp. 5553-5558.
@article{0b3c40b0a46e40c08d3f1392e3ca104a,
title = "Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors",
abstract = "Despite significant improvements in therapy, the prognosis for cancer with bone metastasis is generally poor. Therefore, there is a great need for new therapeutic approaches for metastatic disease. It has been appreciated that tumor cells metastasize to bone using mechanisms similar to those of hematopoietic stem cells (HSC) homing to bone marrow (e.g., CXCL12/CXCR4). It was recently found that prostate cancer cells target the bone marrow microenvironment for HSCs, or the HSC niche, during metastasis. Of importance, these disseminated prostate cancer cells can be mobilized out of the niche with the use of HSC mobilizing agents. These findings suggest that the bone marrow HSC niche is a potential therapeutic target for metastatic disease. Therefore, a hypothesis worth considering is that agents that can disrupt the interactions between tumor cells and the HSC niche may be efficacious when used in conjunction with standard chemotherapeutic agents. Although further understanding of the tumor-niche interactions is needed, the concept of targeting the niche in conjunction with chemotherapy could open up new possibilities to eradicate incurable metastatic diseases.",
author = "Yusuke Shiozawa and Kenneth Pienta and Taichman, {Russell S.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-10-2505",
language = "English (US)",
volume = "17",
pages = "5553--5558",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors

AU - Shiozawa, Yusuke

AU - Pienta, Kenneth

AU - Taichman, Russell S.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Despite significant improvements in therapy, the prognosis for cancer with bone metastasis is generally poor. Therefore, there is a great need for new therapeutic approaches for metastatic disease. It has been appreciated that tumor cells metastasize to bone using mechanisms similar to those of hematopoietic stem cells (HSC) homing to bone marrow (e.g., CXCL12/CXCR4). It was recently found that prostate cancer cells target the bone marrow microenvironment for HSCs, or the HSC niche, during metastasis. Of importance, these disseminated prostate cancer cells can be mobilized out of the niche with the use of HSC mobilizing agents. These findings suggest that the bone marrow HSC niche is a potential therapeutic target for metastatic disease. Therefore, a hypothesis worth considering is that agents that can disrupt the interactions between tumor cells and the HSC niche may be efficacious when used in conjunction with standard chemotherapeutic agents. Although further understanding of the tumor-niche interactions is needed, the concept of targeting the niche in conjunction with chemotherapy could open up new possibilities to eradicate incurable metastatic diseases.

AB - Despite significant improvements in therapy, the prognosis for cancer with bone metastasis is generally poor. Therefore, there is a great need for new therapeutic approaches for metastatic disease. It has been appreciated that tumor cells metastasize to bone using mechanisms similar to those of hematopoietic stem cells (HSC) homing to bone marrow (e.g., CXCL12/CXCR4). It was recently found that prostate cancer cells target the bone marrow microenvironment for HSCs, or the HSC niche, during metastasis. Of importance, these disseminated prostate cancer cells can be mobilized out of the niche with the use of HSC mobilizing agents. These findings suggest that the bone marrow HSC niche is a potential therapeutic target for metastatic disease. Therefore, a hypothesis worth considering is that agents that can disrupt the interactions between tumor cells and the HSC niche may be efficacious when used in conjunction with standard chemotherapeutic agents. Although further understanding of the tumor-niche interactions is needed, the concept of targeting the niche in conjunction with chemotherapy could open up new possibilities to eradicate incurable metastatic diseases.

UR - http://www.scopus.com/inward/record.url?scp=80052504707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052504707&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2505

DO - 10.1158/1078-0432.CCR-10-2505

M3 - Article

VL - 17

SP - 5553

EP - 5558

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -